Home › Trials › NCT07144280

PF-08046054 (SGN-PDL1V) versus docetaxel for PD-L1–positive advanced non-small cell lung cancer

PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

PHASE3 · Pfizer · NCT07144280

This test compares PF-08046054 (SGN-PDL1V) with docetaxel for adults whose PD-L1–positive advanced NSCLC progressed after PD-1/PD-L1 inhibitors, platinum chemotherapy, and targeted treatments when appropriate.

Quick facts

PhasePHASE3
Study typeInterventional
Enrollment680 (estimated)
Ages18 Years and up
SexAll
SponsorPfizer (industry)
Drugs / interventionschemotherapy, prednisone, radiation
Locations305 sites (Alabaster, Alabama and 304 other locations)
Trial IDNCT07144280 on ClinicalTrials.gov

What this trial studies

In this randomized Phase 3 trial, adults with locally advanced or metastatic NSCLC and PD-L1 expression ≥1% are assigned to receive either PF-08046054 given by IV twice every 21-day cycle or docetaxel given by IV once every 21-day cycle. Participants must have disease that progressed on prior PD-1/PD-L1 inhibitors and prior platinum-based chemotherapy, and tumor tissue is required for biomarker analysis. The study compares clinical outcomes and safety between the two arms in this previously treated population. Enrollment allows patients with known actionable genomic alterations and excludes tumors with a neuroendocrine component.

Who should consider this trial

Good fit: Adults with locally advanced unresectable or metastatic NSCLC, PD-L1 expression ≥1%, prior progression after PD-1/PD-L1 inhibitors and platinum chemotherapy, and available tumor tissue for biomarker testing are ideal candidates.

Not a fit: Patients with PD-L1–negative tumors, neuroendocrine histology, or inability to receive IV therapy are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, PF-08046054 could offer a more effective option than docetaxel for patients with PD-L1–positive, previously treated advanced NSCLC.

How similar studies have performed: Other PD-1/PD-L1–targeting therapies have shown benefit in NSCLC, but PF-08046054/SGN-PDL1V is a novel agent being tested directly against docetaxel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of NSCLC with locally advanced, unresectable Stage IIIB or IIIC not eligible for definitive chemoradiotherapy or metastatic (Stage IV: M1a, M1b, or M1c) disease per the American Joint Committee on Cancer (AJCC) Staging Manual, Version 8.0, and the Union for International Cancer Control (UICC) Staging System. Note: Participants with a neuroendocrine component or histology are not eligible.
* PD-L1 expression on ≥1% of tumor cells based on local immunohistochemistry (IHC) testing with an assay utilizing the anti-PD-L1 monoclonal antibody clones 22C3 or SP263.
* Participants who have NSCLC with known AGAs are permitted.
* Able to provide any of the following tumor tissues for biomarker analysis:

  * Archival specimen (preferably collected within 12 months after the last anticancer therapy) (see laboratory manual for details); or
  * De novo biopsy from a tumor lesion, if medically feasible.
* Participants must have received the following therapies and progressed during or relapsed after receiving their most recent prior therapy, or have been intolerant to their most recent therapy:

Participants with no known AGAs must fulfill 1 of the following conditions:

* Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, and unless contraindicated, a PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).
* Experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant, neoadjuvant, or chemoradiotherapy setting and received a PD-(L)1 monoclonal antibody at any time during the course of treatment.

Participants with known AGAs (eg, EGFR mutations, ALK translocations, or other relevant actionable mutations) must fulfill the following conditions:

* Must have received at least 1 relevant AGA-targeted therapy if locally available and, in the opinion of the investigator, additional AGA-targeted therapy is not in the best interest of the participant
* Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, or experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant, neoadjuvant, or chemoradiotherapy setting.
* May have received PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).

Exclusion Criteria

* History of another malignancy within 3 years before the first dose of PF-08046054, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year overall survival \[OS\] ≥90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
* Any central nervous system (CNS) lesions, unless definitively treated with CNS-directed local therapy (surgery and/or radiotherapy). Participants with definitively treated brain metastases are eligible if they meet the following criteria:

  * The participant is on a stable dose of ≤10 mg/day of prednisone or equivalent for at least \>14 days prior to randomization (if requiring steroid treatment).
  * No clinical or radiographic progression in the CNS following CNS-directed definitive radiotherapy and/or surgery.
  * Time since CNS-directed treatment is ≥28 days prior to randomization.
* Participants with a history of leptomeningeal metastasis are excluded.
* Prior treatment with an anti-PD-L1 agent (where indicated per protocol) within 5 half-lives.
* Previous receipt of an MMAE-containing agent or prior docetaxel.

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participations are met.

Where this trial is running

Alabaster, Alabama and 304 other locations

+255 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma, Non-small cell lung cancer NSCLC, NSCLC

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.